Find out who's winning out among hundreds of companies.
News & Analysis: DexCom
Even small investments can have a big payoff down the road.
Which of these two diabetes partners is more likely to be the bigger winner over the long run?
As the prevalence of diabetes has grown, these companies are looking for solutions.
These high-growth industries are where you should consider putting your money to work.
DexCom's shares have been crushing it of late.
Stocks of companies getting a direct tailwind from the COVID-19 pandemic aren't the only top performers in 2020 and over the last year.
The COVID-19 outbreak didn't dampen demand for the company's popular G6 CGM system.
DXCM earnings call for the period ending March 31, 2020.
These three businesses are handling the COVID-19 pandemic with ease.